About Cancertrack^™

Cancertrack^™ is a non-invasive, blood-based liquid biopsy that detects cancer-derived biomarkers. It can be used as often as necessary to monitor disease progression or recurrence and to detect mutations acquired during treatment.

Features

• Coverage of targetable DNA and RNA alterations, including SNVs, short InDels, CNVs and fusions/rearrangements.
• Multi-coordinate and multi-dimensional analysis of DNA and RNA released by cancer cells into the blood.
• Rapid, real-time assessment of the cancer’s changing molecular profile.
• Not dependent on the availability of tumour tissue.
• Can assess biomarkers arising from multiple active disease sites.
• Limit of detection: 0.1% Mutant Allele Frequency.

Suitable For

• People diagnosed with cancer, as a supplement to conventional biopsy and for baseline circulating tumour DNA measurement before treatment.
• People in remission who require active surveillance and monitoring.
• People currently undergoing cancer treatment.
• People who are not responding satisfactorily to standard-of-care therapies.

What Can Cancertrack^™ Reveal?

• Targetable molecular variants.
• Early indication of cancer recurrence or relapse.
• Molecular dynamics in real time.
• Indication of therapy success.
• Molecular signs of drug resistance.

Biomarkers

Cancertrack^™ evaluates SNVs and InDels, Copy Number Alterations and RNA fusion rearrangements across a 52-gene panel.

Why Monitoring Matters

Imaging and scans can take longer to show whether treatment is working or has failed. Cancertrack^™ provides molecular information that can help healthcare professionals monitor response or progression alongside conventional clinical assessment.